Article
SWI/SNF family mutations in advanced NSCLC: genetic characteristics and immune checkpoint inhibitors' therapeutic implication.
ESMO open - 1 Jun 2024
Pang L-L, Zhou H-Q, Zhang Y-X, Zhuang W-T, Pang F, Chen L-J, Liao J, Huang Y-H, Mao T-Q, Mai Z-H, Zhang L, Fang W-F
Abstract excerpt
BACKGROUND: SWItch/Sucrose NonFermentable (SWI/SNF) mutations have garnered increasing attention because of their association with unfavorable prognosis. However, the genetic landscape of SWI/SNF family mutations in Chinese non-small-cell lung cancer (NSCLC) is poorly understood. In addition, the optimal treatment strategy has not yet been determined. PATIENTS AND METHODS: We collected sequencing data on 2027...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.